Clay Siegall’s Passion Developing ADCs for Cancer Treatment and Learning about New Scientific Innovations

Clay Siegall is the founder and chief executive officer of Seattle Genetics since its establishment in 1998. He is a passionate scientist who has developed revolutionary cancer treatments, led innovative scientific projects, and managed groundbreaking projects. Clay enjoys documenting his knowledge on developing scientific innovations through his WordPress blog. On February 27th, Clay shared an article about SpaceX’s plans to send two NASA astronauts beyond the moon. SpaceX is known for setting highly ambitious plans and eventually following through with them. The NASA astronauts are fully aware of the risks involved in the rare space travel and will receive know-how on the best way to handle emergency cases and unique outfits to maintain their visual abilities and give them better sleep at night. The mission will be the first since Apollo went on the last one 45 years ago.

Dr. Clay Siegall is an alumnus of Maryland University with a Bachelors in Zoology. He pursued a Ph.D. in genetics at the George Washington University and worked with the Institute of National Health and the National Cancer Institute between 1988 and 1991. From 1991, Clay joined Bristom Myers Squibb Pharmaceutical Research until 1997. He is on the Council of Ultragenyx Pharmaceuticals, Washington Roundtable, and Alder Biopharmaceuticals. Dr. Clay has honors from various award platforms such as Pacific Northwest Ernst & Young and his former school, the University of Maryland.

Siegall set up Seattle Genetics to develop more efficient cancer treatments. Under his leadership, Seattle has developed various ADCs, earned an FDA approval and signed contracts with Genentech, Pfizer, and GlaxoSmithKline. Currently, they are developing approximately 20 ADCs with support from external and internal programs. Seattle will use the 33A drug that is currently in clinical trials to treat severe myeloid leukemia. Seattle has received 350 million dollars from dealings and 1.2 billion dollars from fundraising events. Dr. Siegall plans to develop more ADCETRIS for more effective treatment of cancer and increase the company’s workforce by hiring 100 professionals in the United States and 20 in Switzerland. Seattle Genetics has the authorization to distribute its FDA approved drugs to more than six nations across the world.